Sugi Predict

Sugi Predict / Compounds / Temsavir

Temsavir

Temsavir

SCHEMBL760768

COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 6/20 1.00
▸ CYP2C9 P11712 5/20 1.00
▸ CYP2D6 P10635 5/20 1.00
▸ CYP3A4 P08684 3/20 1.00
▸ CYP1A2 P05177 2/20 1.00
▸ CYP2C8 P10632 1/20 1.00
▸ CYP2B6 P20813 1/20 1.00
▸ KCNH2 Q12809 1/20 1.00
▸ ALDH1A1 P00352 2/20 0.39
▸ TSHR P16473 1/20 0.38
▸ CNR2 P34972 1/20 0.36
▸ CFTR P13569 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA7 P43166 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Temsavir SCHEMBL30468308 1.00 CYP2C19 (1.00) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL13464991 0.93 CYP2C19 (0.88) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL12527942 0.93 CYP2C19 (0.88) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL25112144 0.93 CYP2C19 (0.86) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL25111993 0.93 CYP2C19 (0.86) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
Temsavir SCHEMBL14867762 0.92 CYP2C19 (0.85) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL24533628 0.92 CYP2C19 (0.85) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL2629160 0.92 CYP2C19 (0.85) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL16618512 0.92 CYP3A4 (0.84) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL25112154 0.91 CYP2C19 (0.84) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090605-A2 COMPOSITIONS AND METHODS COMPRISING TARGETED LIPOSOMAL THERAPEUTIC VACCINES DREXEL UNIVERSITY (US) 2026-04-30 — — WO claimed
US-12564595-B2 Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent SHIONOGI & CO., LTD. (JP) 2026-03-03 — — US claimed
EP-4676493-A1 ASSAYS AND REAGENTS FOR THE DETECTION OF SOLUBLE GP120 Val-Chum, Limited Partnership (CA) 2026-01-14 — — EP claimed
US-20250170172-A1 METHODS FOR TREATING LENTIVIRUS INFECTION JERICHO SCIENCES LLC (US) 2025-05-29 — — US claimed
US-20240425568-A1 COMBINATION THERAPIES FOR HIV INFECTIONS AND USES THEREOF VIIV HEALTHCARE COMPANY (US) 2024-12-26 — — US claimed
US-12157753-B2 Process for preparing Fostemsavir ViiV Healthcare UK (No.4) Limited (GB) 2024-12-03 — — US claimed
EP-4447969-A1 COMBINATION THERAPIES FOR HIV INFECTIONS AND USES THEREOF VIIV Healthcare Company (US) 2024-10-23 — — EP claimed
WO-2024182893-A1 ASSAYS AND REAGENTS FOR THE DETECTION OF SOLUBLE GP120 FINZI ANDRES (CA) 2024-09-12 — — WO claimed
WO-2024137495-A9 FOSTEMSAVIR INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF NAVINTA, LLC (US) 2024-07-25 — — WO claimed
US-20240208980-A1 Fostemsavir Intermediates and Process for the Preparation Thereof NAVINTA, LLC 2024-06-27 — — US claimed
EP-1732604-B1 METHODS OF TREATING HIV INFECTION BRISTOL MYERS SQUIBB CO (US) 2010-07-21 — — EP claimed
US-20090227794-A1 CRYSTALLINE MATERIALS OF 1-(4-BENZOYL-PIPERAZIN-1-YL)-2-[4-METHOXY-7-(3-METHYL-[1,2,4]TRIAZOL-1-YL)-1H-PYRROLO[2,3-C]PYRIDIN-3-YL]-ETHANE-1,2-DIONE BRISTOL-MYERS SQUIBB COMPANY 2009-09-10 — — US claimed
EP-1809631-A1 CRYSTALLINE MATERIALS OF 1-(4-BENZOYL-PIPERAZIN-1-YL)-2-[4-METHOXY-7-(3-METHYL-[1,2,4]TRIAZOL-1-YL)-1H-PYRROLO[2,3-C]PYRIDIN-3-YL]-ETHANE-1,2-DIONE Bristol-Myers Squibb Pharma Company (US) 2007-07-25 — — EP claimed
EP-1732604-A2 METHODS OF TREATING HIV INFECTION Bristol-Myers Squibb Company (US) 2006-12-20 — — EP claimed
WO-2006062658-A1 CRYSTALLINE MATERIALS OF 1-(4-BENZOYL-PIPERAZIN-1-YL)-2-[4-METHOXY-7-(3-METHYL-[1,2,4] TRIAZOL-1-YL)-1H-PYRROLO[2,3-C]PYRIDIN-3-YL]-ETHANE-1,2-DIONE BRISTOL-MYERS SQUIBB COMPANY (US) 2006-06-15 — — WO claimed
WO-2006062655-A2 FORMULATIONS OF 1-(4-BENZOYL-PIPERAZIN-1-YL)-2-[4-METHOXY-7-(3-METHYL-[1,2,4] TRIAZOL-1-YL}-1H-PYRROLO[2,3-C]PYRIDIN-3-YL}-ETHANE-1,2-DIONE BRISTOL-MYERS SQUIBB COMPANY (US) 2006-06-15 — — WO claimed
US-20060100432-A1 Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) 2006-05-11 — — US claimed
US-20060100209-A1 Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione BRISTOL-MYERS SQUIBB COMPANY 2006-05-11 — — US claimed
WO-2005102392-A2 COMBINATIONS FOR TREATING HIV INFECTION BRISTOL-MYERS SQUIBB COMPANY (US) 2005-11-03 — — WO claimed
US-20050215545-A1 Methods of treating HIV infection VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) 2005-09-29 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250170172-A1 METHODS FOR TREATING LENTIVIRUS INFECTION ZC3HAV1, ZC3HAV1L, ZFR CYP2C19 4816/4885CYP2C9 4856/4885CYP2D6 4765/4885
US-20060100432-A1 Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione CCR5, BECN1, CCR1 CYP2C19 1410/4885CYP2C9 2866/4885CYP2D6 3428/4885
US-20050215545-A1 Methods of treating HIV infection CCR5, CD4, CCR1 CYP2C19 1580/4885CYP2C9 3169/4885CYP2D6 2665/4885
US-20090227794-A1 CRYSTALLINE MATERIALS OF 1-(4-BENZOYL-PIPERAZIN-1-YL)-2-[4-METHOXY-7-(3-METHYL-[1,2,4]TRIAZOL-1-YL)-1H-PYRROLO[2,3-C]PYRIDIN-3-YL]-ETHANE-1,2-DIONE CCR5, BECN1, CCR1 CYP2C19 1410/4885CYP2C9 2866/4885CYP2D6 3428/4885
US-12157753-B2 Process for preparing Fostemsavir FIP1L1, CYP3A4, SAMHD1 CYP2C19 13/4885CYP2C9 18/4885CYP2D6 17/4885
US-20240208980-A1 Fostemsavir Intermediates and Process for the Preparation Thereof FIP1L1, CYP3A4, FOS CYP2C19 20/4885CYP2C9 18/4885CYP2D6 49/4885
US-20060100209-A1 Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione CCR5, THPO, KDM5C CYP2C19 1451/4885CYP2C9 3396/4885CYP2D6 2867/4885
US-12564595-B2 Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent RPL35, RPL7, TYMP CYP2C19 1621/4885CYP2C9 1807/4885CYP2D6 1445/4885
US-20240425568-A1 COMBINATION THERAPIES FOR HIV INFECTIONS AND USES THEREOF CD4, TMPRSS4, NFATC1 CYP2C19 3675/4885CYP2C9 3771/4885CYP2D6 4206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.